UNDERWRITING AGREEMENTUnderwriting Agreement • April 17th, 2020 • Arcturus Therapeutics Holdings Inc. • Pharmaceutical preparations • New York
Arcturus Therapeutics Holdings Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,117,650 shares of its common stock, par value $0.001 per share (the “Common Stock”). The 4,117,650 shares of Common Stock to be sold by the Company are called the “Firm Shares.” The Company also proposes to issue and sell to the several Underwriters up to an additional 617,647 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated
